Volume : 09, Issue : 12, December – 2022
Title:
87.DEVELOPMENT AND VALIDATION OF STABILITY INDICATING METHOD FOR SIMULTANEOUS ESTIMATION OF EFAVIRENZ AND PYRAZINAMIDE BY USING RP-HPLC METHOD
Authors :
V.Haritha, P.Prapulla
Abstract :
A basic and specific LC strategy is depicted for the assurance of Efavirenz and pyrazinamide measurements structures. Chromatographic partition was accomplished on a c18 segment utilizing portable stage comprising of a blend of Sodium di hydrogen phosphate cushion (KH2PO4 and K2HPO4) Acetonitrile (40:60v/v), with identification of 252nm. Linearity was seen in the range 100-500 µg/ml Efavirenz (r2 =0.99) and 100-500µg/ml for pyrazinamide (r2 =0.999) for the measure of medications assessed by the proposed strategies was in acceptable concurrence with the name guarantee. The proposed techniques were approved. The exactness of the techniques was evaluated by recuperation learns at three distinct levels. Recuperation tests showed the nonattendance of obstruction from usually experienced pharmaceutical added substances. The strategy was seen as exact as demonstrated by the repeatability examination, indicating %RSD under 2. Every single factual datum demonstrates legitimacy of the techniques and can be utilized for routine investigation of pharmaceutical measurement structure. 400 volumes of pottasium di hydrogen phosphate and Di potasium hidrozen phosphate support and 600 volumes of ACN were readied. The versatile stage was sonicated for 10min to evacuate gases.
Keywords: Efavirenz, Pyrazinamide, RP‐HPLC, Simultaneous estimation.
Cite This Article:
Please cite this article in press V.Haritha et al, Development And Validation Of Stability Indicating Method For Simultaneous Estimation Of Efavirenz And Pyrazinamide By Using RP-HPLC Method.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
:
1. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17. [Article]
2. Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM: A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis. 2005 Jul 15;41(2):e15-8. doi: 10.1086/431208. Epub 2005 Jun 7. [Article]
3. Boshoff HI, Mizrahi V, Barry CE 3rd: Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol. 2002 Apr;184(8):2167-72. (PubMed ID 11914348)
4. Zimhony O, Vilcheze C, Arai M, Welch JT, Jacobs WR Jr: Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob Agents Chemother. 2007 Feb;51(2):752-4. Epub 2006 Nov 13. (PubMed ID 17101678)
5. Montgomery, E.R., Edmanson, A.L., Cook, S.C., Hovsepian, P.K.; Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation; Journal of Pharmaceutical and Biomedical Analysis, (2001); 25: 267–284. doi: 10.1016/S0731-7085(00)00495-7.
6. Viana, O.D.S., Patrícia, F., Medeiros, M., Grangeiro-júnior, S., Muniz, M., Felts, M., et al.; Development and validation of a HPLC analytical assay method for efavirenz tablets : A medicine for HIV infections; Brazilian Journal of Pharmaceutical Sciences, (2011); 47: 97–102.
7. Devrukhakar, P.S., Borkar, R., Shastri, N., Surendranath, K.V.; A validated stability-indicating RP-HPLC method for the simultaneous determination of tenofovir, emtricitabine, and a efavirenz and statistical approach to determine the effect of variables; ISRN Chromatography, (2013); 2013: 1–8.
8. Gupta, S., Kesarla, R., Chotai, N., Omri, A.; Development and validation of reversedphase HPLC gradient method for the estimation of efavirenz in plasma; PLoS ONE, (2017); 12: 1–12. doi: 10.1371/journal.pone.0174777.
9. Palavan, C., Ramaprasad, L.A., Varaprasad, J., Rao, J.V.L.N.S.; A new RPHPLC method for the simultaneous estimation of abacavir, lamivudine and zidovudine in tablet dosage forms; American Journal of Pharmtech Research, (2013); 3: 548–554.
10. Ramaswamy, A., Arul Gnana Dhas, A.S.; Development and validation of analytical method for quantitation of emtricitabine, tenofovir, efavirenz based on HPLC; Arabian Journal of Chemistry, (2018); 11: 275–281. doi: 10.1016/j.arabjc.2014.08.007.
11. Fox, D., Connor, R.O., Mallon, P., Mcmahon, G.; Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma; Journal of Pharmaceutical and Biomedical Analysis, (2011); 56: 785–791. doi: 10.1016/j.jpba.2011.07.041.
12. Maniyar, U.R., Koshe, K., Katariya, M.V., Karva, G.S., Katariya, V.R., Jaiswal, S.; Stability indicating RP-HPLC method development and validation for the determination of potential degradation impurities of efavirenz, emtricitabine and tenofovir in combined pharmaceutical dosage form; Asian Journal of Pharmaceutical Technology and Innovation, (2017); 3: 1–7.